GlassScriptPhysician profile
Andrew I Caster
NPI 1821133067
$4,617.90
in general payments reported to CMS, 2019-2025
17 companies · $234 in 2025
The $234 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $82.42 · 2021: $77.52 · 2022: $1,674 · 2023: $204 · 2024: $2,345 · 2025: $234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,666 · Food and Beverage: $1,118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,666.00 |
| Food and Beverage | $1,117.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $2,387.32 | 2024-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Carl Zeiss Meditec, INC. | $1,250.00 | 2022 | |
| Optos, INC. | $239.47 | 2022 | |
| Novartis Pharmaceuticals Corporation | $138.53 | 2020-2022 | |
| Sun Pharmaceutical Industries INC. | $124.73 | 2020-2023 | Cequa |
| Dompe US, INC. | $119.36 | 2021-2024 | Oxervate |
| Carl Zeiss Meditec USA, INC. | $62.41 | 2022-2023 | Visumax |
| Oyster Point Pharma, INC. | $58.05 | 2022-2025 | Tyrvaya |
| Alcon Vision LLC | $42.52 | 2023-2025 | Simbrinza, Wavelight Ex500 Excimer Laser |
| Abbvie INC. | $42.50 | 2022-2023 | Lumigan, Alphagan P |
| Harrow Eye, LLC | $39.55 | 2025 | Vevye, Iheezo |
| Bausch & Lomb Americas INC. | $22.45 | 2025 | Miebo |
| Biotissue Holdings INC. | $21.54 | 2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Horizon Therapeutics Plc | $17.75 | 2023 | Tepezza |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $16.71 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $15.61 | 2024 | Xdemvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Caster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.